Inovio Pharmaceu Stock Price, News & Analysis

INOVIO (NASDAQ:INO) announced regulatory approval to initiate two clinical trials in China for its COVID-19 DNA vaccine candidate, INO-4800. The trials, sponsored by Advaccine Biopharmaceuticals and Sinovac, will investigate the safety and immunogenicity of a heterologous prime-boost regimen with INO-4800 and Sinovac's CoronaVac. Following successful preclinical results demonstrating strong immune responses, the trials aim to enhance vaccination strategies against emerging COVID-19 variants. If successful, INO-4800 could serve as both a primary and booster vaccine.

INOVIO (NASDAQ: INO) has commenced Phase 2 trials for INO-4700, a DNA vaccine aimed at combating the Middle East Respiratory Syndrome (MERS). This multi-center study, involving around 500 healthy volunteers in Jordan and Lebanon, seeks to assess the safety and immunogenicity of the vaccine. The trial builds on promising results from a previous Phase 1 trial, where 98% of participants developed an immune response. Funded by a $56 million CEPI grant, INOVIO aims to provide a preventive vaccine against MERS, a deadly disease with a high fatality rate.

INOVIO (NASDAQ: INO) will release its second quarter 2021 financial results on August 9, 2021, after market close. A conference call will follow at 4:30 p.m. ET, providing insights into its DNA Medicines Platform and ongoing COVID-19 vaccine developments. The company aims to address financial results and business updates.

Notably, INOVIO's lead candidate VGX-3100 has shown promising results in clearing high-grade cervical lesions in clinical trials, while INO-4800 is currently in Phase 2 trials for COVID-19.

INOVIO (NASDAQ: INO) announced an expansion of its partnership with Advaccine Biopharmaceuticals to conduct a global Phase 3 trial for INO-4800, a DNA vaccine targeting COVID-19. The trial will evaluate the safety and efficacy of a two-dose regimen in adults across Latin America and Asia, with an emphasis on underserved regions. The Phase 3 trial follows promising Phase 2 results showing INO-4800's good tolerance and immunogenicity. The estimated cost of the trial is about $100 million, which will be shared equally with Advaccine.

Geneos Therapeutics announced positive preliminary results from its GT-30 trial, a phase I/II study of personalized vaccine GNOS-PV02 combined with pIL-12 and pembrolizumab for patients with advanced hepatocellular carcinoma (HCC). Out of 10 evaluable patients, the overall response rate was 30%, with 3 achieving partial response and 7 exhibiting disease control. The treatment was generally safe, with no serious adverse events reported. Additionally, interim results from a compassionate use case showed a patient with anaplastic astrocytoma remained recurrence-free for 36 months after treatment.

INOVIO (NASDAQ:INO) announced participation in the Jefferies 2021 Virtual Healthcare Conference on June 1, 2021. Dr. Joseph Kim, President and CEO, will engage in a fireside chat and 1x1 investor meetings at 2:00 PM EDT. INOVIO focuses on developing DNA medicines for infectious diseases, cancer, and HPV-associated conditions, with 15 clinical programs underway. Their proprietary delivery device, CELLECTRA®, allows plasmids to enter cells, generating immune responses without altering individual DNA. INOVIO has conducted over 7,000 applications in clinical trials, showcasing robust efficacy in various programs.

INOVIO (NASDAQ:INO) announced the appointment of Roger D. Dansey, M.D. to its Board of Directors, enhancing its expertise in drug development. Dr. Dansey, currently Chief Medical Officer at Seagen, has extensive experience at Merck, Gilead, and Amgen, where he led notable oncology projects. His expertise will support INOVIO's focus on its late-stage product development programs, including DNA medicines for glioblastoma and COVID-19. This strategic move aims to leverage Dr. Dansey's background to further commercialize INOVIO's innovative treatments.

INOVIO's next-generation Pan-COVID-19 vaccine candidate, INO-4802, has shown strong potential in preclinical studies, inducing robust neutralizing antibodies and T cell responses against several COVID-19 variants, including the original Wuhan strain and the B.1.1.7, B.1.351, and P.1 strains. The dual-track development approach aims to address both pandemic and endemic COVID-19 considerations. Clinical trials for INO-4802 are planned for later this year, enhancing INOVIO's strategy to provide effective cross-variant immunity.

INOVIO (NASDAQ: INO) reported its Q1 2021 financial results with total revenue of $371,000, down from $1.3 million in Q1 2020. The company posted a net loss of $54.4 million, or $0.27 per share, compared to a loss of $32.5 million, or $0.26 per share, in the previous year. INOVIO announced positive Phase 2 trial results for its COVID-19 vaccine candidate, INO-4800, demonstrating safety and immunogenicity across age groups. The company plans a global Phase 3 trial for INO-4800 and continues development of its DNA medicines for HPV-related diseases and cancer.